Detalhe da pesquisa
1.
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
J Transl Med
; 21(1): 75, 2023 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36737752
2.
Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study.
Anticancer Drugs
; 31(2): 190-195, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31850916
3.
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer.
Anticancer Drugs
; 31(3): 292-297, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31850915
4.
A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient.
Future Oncol
; 16(1s): 33-38, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31975628
5.
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Prostate
; 78(12): 889-895, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29707790
6.
Prostate cancer: Developing novel approaches to castration-sensitive disease.
Cancer
; 123(1): 29-42, 2017 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27802360
7.
Targeted Therapies for Prostate Cancer.
Cancer Invest
; 33(7): 276-85, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25951372
8.
Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study.
Anticancer Drugs
; 26(8): 878-83, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26053279
9.
Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
Anticancer Drugs
; 26(8): 884-7, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26053281
10.
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.
Anticancer Drugs
; 26(6): 682-6, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25811963
11.
Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer.
Future Oncol
; 11(18): 2563-74, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26314701
12.
PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.
Tumour Biol
; 35(11): 10601-7, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25195134
13.
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer.
Anticancer Drugs
; 25(4): 472-7, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24394473
14.
Cell-Free DNA: Unveiling the Future of Cancer Diagnostics and Monitoring.
Cancers (Basel)
; 16(3)2024 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38339412
15.
Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival.
Cancer Diagn Progn
; 3(5): 538-542, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37671314
16.
Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Ther Adv Med Oncol
; 15: 17588359231156147, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36895852
17.
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Cancer Invest
; 30(1): 65-71, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22236191
18.
Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine.
Cancers (Basel)
; 14(18)2022 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36139519
19.
Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength.
Front Oncol
; 12: 827822, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35223509
20.
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis.
Ther Adv Med Oncol
; 14: 17588359221110162, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36188485